# Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-III

> **NCT05886829** · PHASE2,PHASE3 · COMPLETED · sponsor: **Dr. Ferrer BioPharma** · enrollment: 157 (actual)

## Conditions studied

- COVID-19
- Symptoms and Signs
- COVID-19 Pandemic
- Coronavirus Disease 2019
- Coronavirus Infections

## Interventions

- **COMBINATION_PRODUCT:** Chlorpheniramine Maleate 0.4% Nasal Spray
- **COMBINATION_PRODUCT:** Placebo

## Key facts

- **NCT ID:** NCT05886829
- **Lead sponsor:** Dr. Ferrer BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-27
- **Primary completion:** 2023-01-19
- **Final completion:** 2023-02-01
- **Target enrollment:** 157 (ACTUAL)
- **Last updated:** 2023-06-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05886829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05886829, "Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-III". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05886829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*